CN101700303B - Traditional Chinese medicine composition used for treating cervical spondylosis - Google Patents
Traditional Chinese medicine composition used for treating cervical spondylosis Download PDFInfo
- Publication number
- CN101700303B CN101700303B CN2009100238771A CN200910023877A CN101700303B CN 101700303 B CN101700303 B CN 101700303B CN 2009100238771 A CN2009100238771 A CN 2009100238771A CN 200910023877 A CN200910023877 A CN 200910023877A CN 101700303 B CN101700303 B CN 101700303B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- cervical spondylosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composite used for treating cervical spondylosis. The composite is prepared from 225 parts of angelica, 105 parts of rhizoma ligustici wallichii, 188 parts of astragalus root, 150 parts of radix salviae miltiorrhizae, 180 parts of spatholobus stem, 300 parts of prepared rehmannia root, 105 parts of lycopodium clavatum, 180 parts of desertliving cistanche, 150 parts of rhizoma drynariae, 300 parts of mulberry twigs, 180 parts of radix puerariae and 225 parts of teasel root according to a conventional process; the composite comprises an oral liquid preparation and granules; and the research of clinical pharmacodynamical experiments proves that the invention has more obvious effect in the aspect of treating the cervical spondylosis in comparison with an original medicine composite.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used for the treatment of cervical spondylosis, belong to technical field of traditional Chinese medicine pharmacy.
Technical background
Cervical spondylosis is common clinical and frequently-occurring disease, and the sickness rate of cervical spondylosis was rising year by year in recent years, and claims rejuvenation trend; Seriously influenced the healthy of people.Chinese patent gazette disclosed the name of being declared by the applicant and was called " a kind of Chinese patent medicine that is used for the treatment of cervical spondylosis " on August 26th, 2009, publication number is the patent application of CN101513470, the weight proportion of forming each herbal medicine raw material of the described Chinese patent medicine of invention is: a Radix Angelicae Sinensis 20-2300 unit of weight, a Rhizoma Chuanxiong 10-1100 unit of weight, a Radix Astragali 15-1900 unit of weight, a Radix Salviae Miltiorrhizae 10-1500 unit of weight, a Caulis Spatholobi 15-1800 unit of weight, a Radix Rehmanniae Preparata 20-3000 unit of weight, a Herba Lycopodii 10-1100 unit of weight, a Herba Cistanches 15-1800 unit of weight, a Rhizoma Drynariae 10-1500 unit of weight, a Ramulus Mori 20-3000 unit of weight, a Radix Puerariae 15-1800 unit of weight, a Radix Dipsaci 20-2300 unit of weight, but we find that the effect of this Chinese patent medicine is desirable not enough in the application process of reality.We grope by a large amount of tests on original basis, have found best prescription proportioning, and clinical pharmacodynamic experiment effect is more remarkable, we routinely technology made oral liquid and granule.
Summary of the invention
The objective of the invention is to: provide a kind of curative effect to treat the Chinese medicine composition of cervical spondylosis more significantly.
The present invention is achieved in that according to components by weight percent and calculates, Chinese medicine composition of the present invention be by following materials of weight proportions routinely prepared form: 225 parts of 225 parts of Radix Angelicae Sinensis, 105 parts of Rhizoma Chuanxiongs, 188 parts of the Radixs Astragali, 150 parts of Radix Salviae Miltiorrhizaes, 180 parts of Caulis Spatholobis, 300 parts of Radix Rehmanniae Preparata, 105 parts of Herba Lycopodiis, 180 parts of Herba Cistanches, 150 parts of Rhizoma Drynariae, 300 parts of Ramulus Moris, 180 parts of Radix Puerariaes, Radix Dipsaci (Radix Rehmanniae Preparata and Radix Rehmanniae Preparata are medical materials of the same race, and Radix Rehmanniae Preparata is called for short Radix Rehmanniae Preparata).Described Chinese medicine composition is oral liquid and granule.
With the granule is example, main pharmacodynamics experimental results show that: 225 parts of raw material weight proportioning Radix Angelicae Sinensis of the present invention, 105 parts of Rhizoma Chuanxiongs, 188 parts of the Radixs Astragali, 150 parts of Radix Salviae Miltiorrhizaes, 180 parts of Caulis Spatholobis, 300 parts of Radix Rehmanniae Preparata, 105 parts of Herba Lycopodiis, 180 parts of Herba Cistanches, 150 parts of Rhizoma Drynariae, 300 parts of Ramulus Moris, 180 parts of Radix Puerariaes, 225 parts of Radix Dipsacis are with former invention weight proportion 1: 30 parts of Radix Angelicae Sinensis, 40 parts of Rhizoma Chuanxiongs, 20 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Caulis Spatholobis, 30 parts in Radix Rehmanniae Preparata, 25 parts of Herba Lycopodiis, 16 parts of Herba Cistanches, 20 parts of Rhizoma Drynariae, 30 parts of Ramulus Moris, 20 parts of Radix Puerariaes, 25 parts of Radix Dipsacis and former invention weight proportion 2: 1000 parts of Radix Angelicae Sinensis, 500 parts of Rhizoma Chuanxiongs, 1500 parts of the Radixs Astragali, 1200 parts of Radix Salviae Miltiorrhizaes, 1500 parts of Caulis Spatholobis, 1500 parts in Radix Rehmanniae Preparata, 900 parts of Herba Lycopodiis, 1400 parts of Herba Cistanches, 800 parts of Rhizoma Drynariae, 1500 parts of Ramulus Moris, 1300 parts of Radix Puerariaes, Radix Dipsaci is compared for 1200 parts, and pharmacodynamic experiment is the result be significantly increased.
The main pharmacodynamics experiment
One, medicine
1, raw material:
A, of the present invention group: Radix Angelicae Sinensis 225g, Rhizoma Chuanxiong 105g, Radix Astragali 188g, Radix Salviae Miltiorrhizae 150g, Caulis Spatholobi 180g, Radix Rehmanniae Preparata 300g, Herba Lycopodii 105g, Herba Cistanches 180g, Rhizoma Drynariae 150g, Ramulus Mori 300g, Radix Puerariae 180g, Radix Dipsaci 225g (by 225 parts of Radix Angelicae Sinensis of the present invention, 105 parts of Rhizoma Chuanxiongs, 188 parts of the Radixs Astragali, 150 parts of Radix Salviae Miltiorrhizaes, 180 parts of Caulis Spatholobis, 300 parts of Radix Rehmanniae Preparata, 105 parts of Herba Lycopodiis, 180 parts of Herba Cistanches, 150 parts of Rhizoma Drynariae, 300 parts of Ramulus Moris, 180 parts of Radix Puerariaes, 225 parts of proportionings of Radix Dipsaci).
1 group of b, former invention: Radix Angelicae Sinensis 240g, Rhizoma Chuanxiong 320g, Radix Astragali 160g, Radix Salviae Miltiorrhizae 80g, Caulis Spatholobi 160g, Radix Rehmanniae Preparata 240g, Herba Lycopodii 200g, Herba Cistanches 128g, Rhizoma Drynariae 160g, Ramulus Mori 240g, Radix Puerariae 160g, Radix Dipsaci 200g (former invention weight proportion 1: 30 parts of Radix Angelicae Sinensis, 40 parts of Rhizoma Chuanxiongs, 20 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Caulis Spatholobis, 30 parts in Radix Rehmanniae Preparata, 25 parts of Herba Lycopodiis, 16 parts of Herba Cistanches, 20 parts of Rhizoma Drynariae, 30 parts of Ramulus Moris, 20 parts of Radix Puerariaes, 25 parts of Radix Dipsacis).
C, 2 groups of former inventions: Radix Angelicae Sinensis 160g, Rhizoma Chuanxiong 80g, Radix Astragali 240g, Radix Salviae Miltiorrhizae 192g, Caulis Spatholobi 240g, Radix Rehmanniae Preparata 240g, Herba Lycopodii 144g, Herba Cistanches 224g, Rhizoma Drynariae 128g, Ramulus Mori 240g, Radix Puerariae 208g, Radix Dipsaci 192g (former invention weight proportion 2: 1000 parts of Radix Angelicae Sinensis, 500 parts of Rhizoma Chuanxiongs, 1500 parts of the Radixs Astragali, 1200 parts of Radix Salviae Miltiorrhizaes, 1500 parts of Caulis Spatholobis, 1500 parts in Radix Rehmanniae Preparata, 900 parts of Herba Lycopodiis, 1400 parts of Herba Cistanches, 800 parts of Rhizoma Drynariae, 1500 parts of Ramulus Moris, 1300 parts of Radix Puerariaes, 1200 parts of Radix Dipsacis).
2, a, b, c method for making are: above 12 flavors, decoct with water three times, and add 10 times of water gagings for the first time and decocted 1.5 hours, second and third time respectively adds 8 times of water gagings, each 1 hour, filters, merging filtrate is evaporated to the clear paste of relative density 1.15～1.25 (50 ℃), vacuum drying, pulverize, add an amount of dextrin, mixing is made granule, drying, promptly.
Two, test and result
(1) influence of xylol induced mice auricle edema
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g.
2, medicine: of the present invention group, 1 group of former invention and 2 groups of dosage of former invention are 3.6g crude drug/kg; Ether; Dimethylbenzene.Medicine
Before experiment, dispose gastric infusion with distilled water.
Experimental technique
40 of Kunming mouses, male and female half and half, body weight 18～22g is divided into 4 groups at random, 10 every group.Matched group is irritated the distilled water of stomach with volume; Of the present invention group, 1 group of former invention and 2 groups of gastric infusions of former invention are 3.6g crude drug/kg.Successive administration 3d, every day 1 time is behind the last administration 1h, only be applied to two sides inside and outside the auris dextra with 100% dimethylbenzene 0.04ml/, left ear behind the 1h is put to death the mice etherization in contrast, ears are laid round auricle respectively with 8mm diameter macropore device under subtracting at the same position of mice, weigh.Calculate mice auricle swelling degree (weight difference of mouse right ear sheet and left auricle).Organize a significance test.
Experimental result: see Table 1
The influence of swelling due to the table 1 pair Mice Auricle dimethylbenzene (x ± s)
Compare * P＜0.05 with matched group, * * P＜0.01; With of the present invention group than Δ P＜0.05.
The result shows: of the present invention group, 1 group of former invention and former invention can obviously suppress dimethylbenzene induced mice ease auricle swelling for 2 groups.Of the present invention group of mice auricle swelling degree is starkly lower than matched group (P＜0.01); Compare for 2 groups with 1 group of former invention, former invention for of the present invention group, xylol induced mice ease auricle swelling of the present invention has significant inhibitory effect (P＜0.05), illustrates that antiinflammatory action of the present invention obviously is better than 2 groups of 1 group of former invention and former inventions.
Two, the influence of Dichlorodiphenyl Acetate induced mice writhing response
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g.
2, medicine: of the present invention group, 1 group of former invention and 2 groups of dosage of former invention are 3.6g crude drug/kg; Acetic acid.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
40 of kunming mices, male and female half and half, body weight 18～22g is divided into 4 groups at random, 10 every group.Matched group is irritated the distilled water of stomach with volume; Of the present invention group, 1 group of former invention and 2 groups of gastric infusions of former invention are 3.6g crude drug/kg.Successive administration 7d, behind the last administration 1h, the equal lumbar injection 0.6% acetic acid 0.2ml/ of every Mus, mouse writhing number of times in the record 15min, and calculate each and organize analgesia percentage rate.Organize a significance test.
Experimental result: see Table 2
The influence of table 2 Dichlorodiphenyl Acetate induced mice writhing response (x ± s)
Compare * * P＜0.01 with matched group; With of the present invention group of Δ P＜0.05.
The result shows: of the present invention group, 1 group of former invention and 2 groups of Dichlorodiphenyl Acetate induced mice of former invention are turned round body and are had the obvious suppression effect.Compare the difference (P＜0.01) that utmost point significance is arranged with matched group for of the present invention group; Compare for 2 groups with 1 group of former invention, former invention for of the present invention group, of the present invention group of Dichlorodiphenyl Acetate induced mice turned round body and had significant inhibitory effect (P＜0.05), illustrates that analgesic activity of the present invention obviously is better than 2 groups of 1 group of former invention and former inventions.
Three, to the influence of stasis syndrome rat microcirculation disturbance
Experiment material
1, animal: Wistar kind rat, male and female have concurrently, body weight 230～250g.
2, medicine: of the present invention group, 1 group of former invention and 2 groups of dosage of former invention are 2.5g crude drug/kg; Adrenalin hydrochloride; Pentobarbital sodium.Medicine disposes with 5% glucose solution before experiment, intravenous administration.
Experimental technique
50 of Wistar rats, male and female half and half, body weight 230～250g is divided into 5 groups at random, every group 10, except that the blank group, 2 times 0.1% adrenalin hydrochlorides of every rat skin lower injection of other 4 treated animals, each 0.08ml/100g, interval 4h, the centre is carried out ice-water bath 1 time, and 0～2 ℃ of temperature is soaked 5min.After so handling, water 12h is can't help in the animal fasting, and 2d carries out the microcirculation experiment.Blank group and model control group all give 5% glucose solution 0.2ml/100g; Of the present invention group, 1 group of former invention and 2 groups of dosages of former invention are 2.5g crude drug/kg.Animal with pentobarbital sodium 40mg/kg intraperitoneal injection of anesthesia, along hunter's line longitudinal incision stomach wall 2～3cm, is pulled out ileum portion gently, mesentery is placed fill on the tyrode constant temperature perfusion groove.Change by microcirculation microscope and image processing system direct observation mesentery microcirculation behind the sublingual vein drug administration by injection.Observe the value of administration metarteriole blood flow rate (BFVA), arteriole caliber (DA), capillary vessel number (N).Organize a significance test.
Experimental result: see Table 3
The influence of table 3 pair stasis syndrome rat microcirculation disturbance (x ± s)
Compare with model control group: * * P＜0.01, with of the present invention group than Δ P＜0.05.
The result shows: of the present invention group, former invention group 1 and former invention are organized 2 groups and all can obviously be improved stasis syndrome rat microcirculation disturbance, have function of promoting blood circulation to disperse blood clots, have compared utmost point significant difference (P＜0.01) with matched group.Compare for 2 groups with 1 group of former invention, former invention for of the present invention group, of the present invention group has significant effect (P＜0.05) to improving stasis syndrome rat microcirculation disturbance, illustrates of the present inventionly to improve the effect of stasis syndrome microcirculation of rats and obviously be better than 2 groups of 1 group of former invention and former inventions.
Four, to the effect of rat assist agent arthritis Secondary cases pathological changes
Experiment material
1, animal: Wistar kind male rat, body weight 230～250g.
2, medicine: of the present invention group, 1 group of former invention and 2 groups of dosage of former invention are 2.5g crude drug/kg.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
40 of Wistar kind male rats, body weight 230～250g, be divided into 4 groups at random, every group 10, measure right back sufficient sole of the foot volume with the volume capillary tube method, then from right back sufficient sole of the foot intradermal injection not formula Freund's complete adjuvant 0.05ml cause inflammation, 19d gastric infusion thing behind the Yu Zhiyan, matched group are irritated the distilled water of stomach with volume; Of the present invention group, 1 group of former invention and 2 groups of gastric infusions of former invention are 2.5g crude drug/kg.Successive administration 7d, every day 1 time, 26d measures right back sufficient sole of the foot volume again behind the Yu Zhiyan so that before scorching and the difference that causes scorching back 26d volume as the swelling degree.Organize a significance test.
Experimental result: see Table 4
The effect of table 4 pair rat assist agent arthritis Secondary cases pathological changes (x ± s)
Compare * * P＜0.01 with matched group; With of the present invention group than Δ P＜0.05.
The result shows: 2 groups of of the present invention group, 1 group of former invention and former inventions have the obvious suppression effect to rat assist agent arthritis Secondary cases pathological changes.Compare the difference (P＜0.01) that utmost point significance is arranged with matched group for of the present invention group; Compare for 2 groups with 1 group of former invention, former invention for of the present invention group, of the present invention group has significant inhibitory effect (P＜0.05) to rat assist agent arthritis Secondary cases pathological changes, illustrates that effect that the present invention treats adjuvant-induced arthritis Secondary cases pathological changes obviously is better than 2 groups of 1 group of former invention and former inventions.
Conclusion: the present invention is stronger than effects such as the antiinflammatory of 1 group of former invention, 2 groups of former inventions, analgesia, microcirculation improvement, inhibition adjuvant-induced arthritis Secondary cases pathological changes, and the present invention compares for 2 groups with 1 group of former invention, former invention, and pharmacological action significantly strengthens.
The specific embodiment
Prescription:
Radix Angelicae Sinensis 225g Rhizoma Chuanxiong 105g Radix Astragali 188g Radix Salviae Miltiorrhizae 150g
Caulis Spatholobi 180g Radix Rehmanniae Preparata 300g Herba Lycopodii 105g Herba Cistanches 180g
Rhizoma Drynariae 150g Ramulus Mori 300g Radix Puerariae 180g Radix Dipsaci 225g.
1, process for producing granula of the present invention: above 12 flavors, decoct with water three times, add 10 times of water gagings for the first time and decocted 1.5 hours, second and third time respectively adds 8 times of water gagings, each 1 hour, filters, merging filtrate is evaporated to the clear paste of relative density 1.15～1.25 (50 ℃), vacuum drying, pulverize, add an amount of dextrin, mixing, make granule, drying, pack promptly gets granule of the present invention.
2, process for producing granula of the present invention: above 12 flavors, decoct with water three times, add 10 times of water gagings for the first time and decocted 1.5 hours, second and third time respectively adds 8 times of water gagings, each 1 hour, filters, merging filtrate leaves standstill, and filters, filtrate decompression is concentrated into the clear paste of relative density 1.03～1.06 (55～65 ℃), adds Mel, cyclamate, potassium sorbate, adds water to 1000ml, stir evenly, filter fill, sterilization promptly gets oral liquid of the present invention.
Claims (6)
1. Chinese medicine composition that is used for the treatment of cervical spondylosis, it is characterized in that: it is made up of the medical material of following weight proportion: 225 parts of Radix Angelicae Sinensis, 105 parts of Rhizoma Chuanxiongs, 188 parts of the Radixs Astragali, 150 parts of Radix Salviae Miltiorrhizaes, 180 parts of Caulis Spatholobis, 300 parts of Radix Rehmanniae Preparata, 105 parts of Herba Lycopodiis, 180 parts of Herba Cistanches, 150 parts of Rhizoma Drynariae, 300 parts of Ramulus Moris, 180 parts of Radix Puerariaes, 225 parts of Radix Dipsacis.
2. according to the Chinese medicine composition of the described treatment cervical spondylosis of claim 1, it is characterized in that: the dosage form of described Chinese medicine composition is: oral liquid and granule.
3. preparation method for the treatment of the Chinese medicine composition of cervical spondylosis, it is characterized in that: get 225 parts of Radix Angelicae Sinensis, 105 parts of Rhizoma Chuanxiongs, 188 parts of the Radixs Astragali, 150 parts of Radix Salviae Miltiorrhizaes, 180 parts of Caulis Spatholobis, 300 parts of Radix Rehmanniae Preparata, 105 parts of Herba Lycopodiis, 180 parts of Herba Cistanches, 150 parts of Rhizoma Drynariae, 300 parts of Ramulus Moris, 180 parts of Radix Puerariaes, 225 parts of Radix Dipsacis, the oral liquid that is mixed and made into correctives and antiseptic behind the effective component extracting according to a conventional method.
4. a kind of preparation method for the treatment of the Chinese medicine composition of cervical spondylosis according to claim 3 is characterized in that: the correctives of described oral liquid formulations is Mel and cyclamate, and antiseptic is a potassium sorbate.
5. a kind of preparation method for the treatment of the Chinese medicine composition of cervical spondylosis according to claim 3, it is characterized in that: get Radix Angelicae Sinensis 225g, Rhizoma Chuanxiong 105g, Radix Astragali 188g, Radix Salviae Miltiorrhizae 150g, Caulis Spatholobi 180g, Radix Rehmanniae Preparata 300g, Herba Lycopodii 105g, Herba Cistanches 180g, Rhizoma Drynariae 150g, Ramulus Mori 300g, Radix Puerariae 180g, Radix Dipsaci 225g, decoct with water three times, adding for the first time 10 times of water gagings decocted 1.5 hours, second, respectively add 8 times of water gagings for three times, each 1 hour, filter, merging filtrate leaves standstill, and filters, relative density was the clear paste of 1.03-1.06 when filtrate decompression was concentrated into 55-65 ℃, add Mel, cyclamate, potassium sorbate adds water to 1000ml, stirs evenly, filter, fill, sterilization promptly gets oral liquid.
6. preparation method for the treatment of the Chinese medicine composition of cervical spondylosis, it is characterized in that: get Radix Angelicae Sinensis 225g, Rhizoma Chuanxiong 105g, Radix Astragali 188g, Radix Salviae Miltiorrhizae 150g, Caulis Spatholobi 180g, Radix Rehmanniae Preparata 300g, Herba Lycopodii 105g, Herba Cistanches 180g, Rhizoma Drynariae 150g, Ramulus Mori 300g, Radix Puerariae 180g, Radix Dipsaci 225g, decoct with water three times, adding for the first time 10 times of water gagings decocted 1.5 hours, second, respectively add 8 times of water gagings for three times, each 1 hour, filter, merging filtrate, relative density is the clear paste of 1.15-1.25 when being evaporated to 50 ℃, and vacuum drying is pulverized, add dextrin, mixing is made granule, drying, pack promptly gets granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100238771A CN101700303B (en) | 2009-09-11 | 2009-09-11 | Traditional Chinese medicine composition used for treating cervical spondylosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100238771A CN101700303B (en) | 2009-09-11 | 2009-09-11 | Traditional Chinese medicine composition used for treating cervical spondylosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101700303A CN101700303A (en) | 2010-05-05 |
| CN101700303B true CN101700303B (en) | 2011-07-27 |
Family
ID=42155246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100238771A Active CN101700303B (en) | 2009-09-11 | 2009-09-11 | Traditional Chinese medicine composition used for treating cervical spondylosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101700303B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104642679A (en) * | 2015-03-23 | 2015-05-27 | 万雄集团股份有限公司 | Coffee beverage capable of relieving ache of neck and shoulder and preparation method of coffee beverage |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513470A (en) * | 2009-04-16 | 2009-08-26 | 陕西东泰制药有限公司 | Chinese patent medicine for treating cervical vertebra disease |
-
2009
- 2009-09-11 CN CN2009100238771A patent/CN101700303B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513470A (en) * | 2009-04-16 | 2009-08-26 | 陕西东泰制药有限公司 | Chinese patent medicine for treating cervical vertebra disease |
Non-Patent Citations (3)
| Title |
|---|
| 俞晓东.中药治疗腰椎间盘突出症的研究现况.《甘肃中医》.2009,第22卷(第3期),76-79. * |
| 柳景红.中医药治疗脊髓型颈椎病的研究进展.《中医药导报》.2007,第13卷(第2期),88-91. * |
| 薛怀宝. 中医药治疗腰椎间盘突出症近况.《贵阳中医学院学报》.2009,第31卷(第1期),65-68. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101700303A (en) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104258310A (en) | Traditional Chinese medicine for curing hepatic depression syndrome type melancholia | |
| CN101744895A (en) | Medical preparation for treatment of rheumatism, lumbar vertebra disease and cervical spondylosis | |
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN104027517A (en) | Traditional Chinese medicine for treating acute enteritis | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN101700303B (en) | Traditional Chinese medicine composition used for treating cervical spondylosis | |
| CN102008561B (en) | Mixture for treating depression | |
| CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN101112552A (en) | Dermatosis treating medicine and method for preparing the same | |
| CN103417716B (en) | Hypoglycemic Tongluo tablet for treating diabetic peripheral neuropathy | |
| CN102178769A (en) | Medical composition for preventing or treating postpartum constipation of puerpera | |
| CN102441113B (en) | Bergenia scopulosa traditional Chinese medicinal composition and preparation method thereof | |
| CN104906402A (en) | Chinese medicine preparation for treating refractory headache and preparation method thereof | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN102940709A (en) | Medicine composition for treating gout | |
| CN103006832B (en) | Chinese herbal combination for raising blood platelets and preparation method of combination | |
| CN101884664B (en) | Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN104147270A (en) | Traditional Chinese medicine for treating acute hepatitis | |
| CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN102961679B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN104027515A (en) | Traditional Chinese medicine used for treating intestinal obstruction | |
| CN102961676B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN103751272B (en) | Treat the Chinese medicine composition and its extract of ankylosing spondylitis | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |